Phase 2
N=300
Clinical Trial of Two Study Drinks in Detoxification of Environmental Toxicants and Carcinogens
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT03978117 ↗Enrolled (actual)
300
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Carcinogen Detoxification of Metabolites in Urine. — 7.26; 6.11; 3052.39; 1843.29 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Freeze Dried Watercress Preparation (Dietary_supplement); Placebo Preparation (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Carcinogen Detoxification of Metabolites in Urine. |
7.26; 6.11; 3052.39; 1843.29; 329.25; 316.70 | — |
Summary
The goal of this research is to determine if consuming one of two study drinks will help enhance the detoxification of multiple environmental toxicants and cancer causing agents, particularly in subjects who are null for glutathione-S-transferase M1 (GSTM1), glutathione-S-transferase T1 (GSTT1), or both. If our research supports this idea, this drink could be an inexpensive dietary component, which could promote good health.
Eligibility Criteria
Inclusion Criteria
- Adult Male or female. Participants can be smokers or non-smokers
- In good physical health
- In stable and good mental health
- Not using any medications that may affect the Nrf2 pathway
- Women who are not pregnant or nursing or planning to become pregnant
- Participants have provided written informed consent to participate in the study
Exclusion Criteria
- Significant immune system disorders, respiratory diseases, kidney or liver diseases or any other medical disorders that may affect biomarker data as determined by the licensed medical professional
- Vital signs outside of the allotted range
- Not willing to abstain from eating cruciferous vegetables during the course of the study
Data sourced from ClinicalTrials.gov (NCT03978117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.